We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Gives Unanimous ‘No’ to Y-mAbs Biologic for Pediatric Neuroblastoma
FDA Panel Gives Unanimous ‘No’ to Y-mAbs Biologic for Pediatric Neuroblastoma
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 16-0 on Friday against recommending Y-mAbs Therapeutics’ biologic candidate for the treatment of central nervous system/leptomeningeal (CNS/LM) metastases in children with neuroblastoma who have had the standard treatment for CNS disease.